For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and h ... Show More
Today
After a Crushing Defeat, Trump Doubles Down
After a stinging rebuke last week at the polls, President Trump announced that he would elevate Stephen Miller — a driving force behind some of the most polarizing policies of Mr. Trump’s second term — to chief of staff.Maggie Haberman and Jonathan Swan, White House reporters for ... Show More
31m 14s
Nov 7
Introducing ‘METRO’ From Serial Productions
Today, we’re sharing an episode from a brand-new show called “METRO,” made by the Serial podcast team and the reporters here at The Times who cover New York City.Every other week, Sarah Koenig and her team will tell stories about the city and its most fascinating raw material: Ne ... Show More
41m 42s
Jul 2023
Sawbones: Patents vs. Life-Saving Drugs
<p>John Green recently made a video asking Johnson & Johnson not to extend their patent on a tuberculosis drug, which would keep it exclusive and expensive. Dr. Sydnee and Justin talk about how drug patents work, the recent (good) update about bedaquiline specifically, and the ne ... Show More
38m 46s
Oct 2021
Sick Money (Pt 1): Exposing the drug companies' price gouging tactics
In the first of two episodes this week, we're taking a deep dive into the pharmaceutical industry. How much does the medication you take actually cost? What if a company came along and bought the rights to a particular drug and started charging double, triple, or even 10,000 time ... Show More
29m 31s